Table 1 |
||
|
Targeted therapies in clinical development |
||
| Target |
Agent |
Agent class |
|
|
||
| EGFR |
IMC-C225 Cetuximab, Erbitux (Imclone) |
Monoclonal antibody |
| ABX-EGF (Abgenix) |
Monoclonal antibody |
|
| EMD 72000 (Merck KgaA Darmstadt) |
Monoclonal antibody |
|
| ZD 1839 gefitinib, Iressa (AstraZeneca) |
Small molecule kinase inhibitor |
|
| OSI-774, erlotinib, Tarceva(OSI-Pharmaceuticals) |
Small molecule kinase inhibitor |
|
| CI-1033/PD183805 (Pfizer) |
Small molecule kinase inhibitor |
|
| EKB-569 (Wyeth Ayerst) |
Small molecule kinase inhibitor |
|
| GW2016/572016(GlaxoSmithKline) |
Small molecule kinase inhibitor |
|
| HER2/neu |
Trastuzumab, Herceptin(Genentech) |
Monoclonal antibody |
| 2C4 (Genentech) |
Monoclonal antibody |
|
| 17-AAG |
Geldanamycin derivative inhibits HSP90 |
|
| TAK-165(Takeda Pharmaceuticals) |
Small molecule inhibitor |
|
| GW2016/572016(GlaxoSmithKline) |
Small molecule kinase inhibitor |
|
| CP 724, 714 (Pfizer) |
Small molecule inhibitor |
|
| Ras |
R115777(Johnson and Johnson) |
Farnesyl transferase inhibitor |
| SCH66336 (Schering-Plough) |
Farnesyl transferase inhibitor |
|
| BMS214662(Bristol Myers Squibb) |
Farnesyl transferase inhibitor |
|
| CT-2584HMS (Cell Therapeutics) |
Farnesyl transferase inhibitor |
|
| Raf |
BAY 43-9006 (Onyx/Bayer) |
Small molecule kinase inhibitor |
| MEK |
PD 184352/CI-1040 (Pfizer) |
Small molecule kinase inhibitor |
| PKC-α |
ISIS 3521/LY900003 Affinitak(ISIS Pharmaceuticals) |
Antisense oligonucleotide |
| CGP41251/PKC412 (Novartis) |
Staurosporine analogue |
|
| Bryostatin-1 |
Small molecule kinase inhibitor |
|
| UCN-01 (Kyowa Hakko Kogyo) |
Staurosporine analogue |
|
| PKC-β |
LY333531 (Eli Lilly) |
Small molecule kinase inhibitor |
| Akt |
17-AAG |
Inhibitor of HSP90 |
| Perifosine (Zenataris) |
Alkylphospholipid |
|
| mTOR |
CCI-779 (Wyeth) |
Inhibits mTOR kinase by binding to FKBP |
| RAD001 (Novartis) |
Inhibits mTOR kinase by binding to FKBP |
|
|
|
||
|
EGFR, epidermal growth factor receptor; MEK, MAP kinase/ERK kinase; mTOR, mammalian target of rapamycin; PKC, protein kinase C. |
||
|
de Bono et al. Breast Cancer Res 2003 5:154 doi:10.1186/bcr597 |
||